Form 4: VYNE Director Elisabeth Little Receives Stock Options

VYNE Therapeutics Director Elisabeth Sandoval Little was granted 20,000 stock options as part of her annual non-employee director award.

Summary

• Elisabeth Sandoval Little, a Director at VYNE Therapeutics Inc. (VYNE), acquired 20,000 stock options.
• The transaction date for this grant was December 12, 2025.
• Each stock option has an exercise price of $0.3756.
• The options are scheduled to vest on December 12, 2026, contingent upon continuous service by the reporting person.
• The expiration date for these stock options is December 11, 2035.
• This grant represents the annual award provided to non-employee directors of the Issuer.

Sentiment

Score: 5

Explanation: The filing reports a routine grant of stock options to a non-employee director as part of their annual compensation, which is a neutral event regarding company performance or outlook.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Grant of 20,000 stock options to Elisabeth Sandoval Little, a non-employee director, as part of her annual compensation.

Stakeholder Impact

• Shareholders: Potential minor dilution if options are exercised in the future, which is standard for equity compensation.
• Elisabeth Sandoval Little (Director): Receives additional equity incentive, aligning her interests with those of the shareholders.

Next Steps

• The granted stock options will vest on December 12, 2026, subject to the director's continuous service.

Key Dates

Keywords

VYNE Therapeutics, VYNE, Form 4, Insider Transaction, Stock Options, Director Compensation, Elisabeth Sandoval Little